Phase II Study of the HDAC Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (CALGB 30304)
- Citation:
- J Thorac Oncol vol 5 (10) 1644-1648
- Year:
- 2010
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- Parents:
- None
- Children:
- None
- Program:
- OGC
- Primary Committee:
- Respiratory
- Sec. Committees:
- Pharmas:
- Grants:
- U10 CA047577, U10 CA032291, U10 CA077658, U10 CA031946, U10 CA033601, U10 CA045389, U10 CA180821, U10 CA077597, U10 CA059518, U10 CA114558, U10 CA045418, U10 CA077440, U10 CA041287, U10 CA041287-14, U10 CA033601-30, U10 CA077658-14
- Corr. Author:
- Authors:
- G.A. Otterson L. Hodgson H. Pang E.E. Vokes
- Networks:
- Study
- CALGB-30304
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Romidepsin, Small Cell Lung Cancer, Epigenetics